Essam Nairoukh1,
Syed Sikandar Shah2 
,
Jamil Ahmad3,
Ashfaq Ahmad Shah Bukhari4,
Aftab Alam2
For correspondence:- Syed Shah Email: syed.sikandar@rakmhsu.ac.ae Tel:+971 56 6410232
Received: 25 July 2025 Accepted: 15 January 2026 Published: 31 January 2026
Citation: Nairoukh E, Shah SS, Ahmad J, Bukhari AA, Alam A. Assessing COVID-19 vaccine side effects among the general population in Jordan: A nationwide perspective. Trop J Pharm Res 2026; 25(1):71-80 doi: https://dx.doi.org/10.4314/tjpr.v25i1.10
© 2026 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To assess the nature of COVID-19 vaccine side effects in Jordan, addressing public concerns and vaccine hesitancy. Methods: A total of 405 participants were surveyed, having received one to four doses of the COVID-19 vaccines approved in Jordan. Data were collected via a self-administered online survey created with Google Forms and shared through social media platforms. Results: Of these, 355 participants met the inclusion criteria - primarily female (57.7 %) and educated to a bachelor’s level (53.5 %). Most had no serious medical conditions (75.5 %) and had received two doses (71.3 %), with Pfizer-BioNTech being the most common (56.9 %). Side effects were reported by 68.1 %, mostly minor, such as injection site pain (45.8 %) and fatigue (42.7 %). Severe effects (10.7 %), including anaphylaxis and dyspnea, were infrequent and non-hospitalized. Conclusion: This study affirms the high safety profile of COVID-19 vaccines, with most side effects being mild and short-lived. The rarity of severe adverse events underscores the vaccines’ overall benefits, supporting their continued use in public health efforts. Transparent communication and ongoing safety monitoring remain essential to enhance public confidence and combat vaccine hesitancy.
Fulltext in PDF